Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.

Authors

null

Andres Poveda

Initia Oncology, Hospital Quirónsalud, Valencia, Spain

Andres Poveda , Stephanie Lheureux , Nicoletta Colombo , David Cibula , Kristina Lindemann , Johanne I Weberpals , Maria Bjurberg , Ana Oaknin , Magdalena Sikorska , Antonio Gonzalez Martin , Radoslaw Madry , Maria Jesus Rubio Pérez , Richard Davidson , Christopher Blakeley , James Bennett , Alan Barnicle , Erik Skof

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03402841

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6057)

DOI

10.1200/JCO.2020.38.15_suppl.6057

Abstract #

6057

Poster Bd #

228

Abstract Disclosures